Phase 1 Study of Oral IACS-6274 Alone or with Bevacizumab and Paclitaxel, or with Capivasertib for Advanced Solid Tumors

What this Trial Is About

Researchers are studying the safety and tolerability of the oral glutaminase inhibitor IACS-6274 as a single treatment and in combination with other drugs for patients with advanced solid tumors. The study aims to find the highest dose patients can tolerate when IACS-6274 is given alone, with bevacizumab and paclitaxel, or with capivasertib. This phase 1 trial also looks at how the drug behaves in the body and its preliminary effects on tumors in different patient groups, including those with specific genetic markers or cancer types. Participants are assigned to one of three groups Part A receives IACS-6274 by mouth alone Part B receives IACS-6274 orally along with paclitaxel and bevacizumab given intravenously Part C receives IACS-6274 orally with capivasertib by mouth. The study includes a dose-escalation phase to determine safe dosing and a dose-expansion phase to further evaluate the treatments. Some patients may also choose to provide tissue samples for future biomarker studies. During the trial, patients will have regular assessments including physical exams, imaging scans, and laboratory tests to monitor safety, drug effects, and tumor response. Researchers will track adverse events for up to 90 days after treatment begins. The study requires patients to have measurable tumor lesions and adequate organ function. Participation includes ongoing monitoring of heart function and the collection of biopsy samples where feasible. The study is expected to continue until mid-2028.

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors